File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of Sandostatin® LAR® on serum leptin levels in patients with acromegaly

TitleEffect of Sandostatin® LAR® on serum leptin levels in patients with acromegaly
Authors
Issue Date2001
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 2001, v. 54 n. 1, p. 31-35 How to Cite?
AbstractOBJECTIVE. Serum leptin levels are decreased in patients with acromegaly and rise after GH is normalized by surgical treatment. We have evaluated the effect of Sandostatin® LAR® on leptin levels in acromegalic patients since there are recent data to suggest that somatostatin, in addition to its GH lowering effect, also reduces serum leptin levels in humans. METHODS. Nineteen patients with active acromegaly were studied. Eleven patients received monthly injection of Sandostatin® LAR® and eight patients underwent transsphenoidal surgery. Serum concentrations of leptin, GH, IGF-1 and insulin were measured before and after treatment. RESULTS. Serum leptin concentrations were lower in patients with active acromegaly than controls matched for age, sex and body mass index (BMI) [2.79 μg/l (2.60) vs. 4.41 μg/l (5.07); median (interquartile range); P< 0.01]. A positive correlation between serum leptin concentrations and BMI was observed in the controls (r = 0.46, P < 0.05) but not in the acromegalic patients before treatment (r = 0.32, ns). In the group of patients treated with Sandostatin® LAR®, a marked reduction in GH and IGF-1 was achieved by week 8 and GH and IGF-1 remained suppressed throughout the 6 months of treatment. There was no change in BMI. A significant increase in leptin levels only became evident after 6 months of treatment [2.99 μg/l (2.60) vs. 4.21 μg/l (3.84), P< 0.05]. Leptin levels also significantly increased after transsphenoidal surgery [3.05 μg/l (5.73) vs. 5.19 μg/l (4.93), P< 0.05]. The positive correlation between serum leptin concentrations and BMI was restored in acromegalic patients both after treatment with Sandostatin® LAR® (r= 0.62, P < 0.05) and after surgery (r = 0.81, P < 0.05). CONCLUSION. Leptin concentrations were decreased in patients with active acromegaly and lowering GH by either Sandostatin® LAR® or transsphenoidal surgery led to an increase in leptin concentrations.
Persistent Identifierhttp://hdl.handle.net/10722/162511
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_HK
dc.contributor.authorTso, AWKen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2012-09-05T05:20:38Z-
dc.date.available2012-09-05T05:20:38Z-
dc.date.issued2001en_HK
dc.identifier.citationClinical Endocrinology, 2001, v. 54 n. 1, p. 31-35en_HK
dc.identifier.issn0300-0664en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162511-
dc.description.abstractOBJECTIVE. Serum leptin levels are decreased in patients with acromegaly and rise after GH is normalized by surgical treatment. We have evaluated the effect of Sandostatin® LAR® on leptin levels in acromegalic patients since there are recent data to suggest that somatostatin, in addition to its GH lowering effect, also reduces serum leptin levels in humans. METHODS. Nineteen patients with active acromegaly were studied. Eleven patients received monthly injection of Sandostatin® LAR® and eight patients underwent transsphenoidal surgery. Serum concentrations of leptin, GH, IGF-1 and insulin were measured before and after treatment. RESULTS. Serum leptin concentrations were lower in patients with active acromegaly than controls matched for age, sex and body mass index (BMI) [2.79 μg/l (2.60) vs. 4.41 μg/l (5.07); median (interquartile range); P< 0.01]. A positive correlation between serum leptin concentrations and BMI was observed in the controls (r = 0.46, P < 0.05) but not in the acromegalic patients before treatment (r = 0.32, ns). In the group of patients treated with Sandostatin® LAR®, a marked reduction in GH and IGF-1 was achieved by week 8 and GH and IGF-1 remained suppressed throughout the 6 months of treatment. There was no change in BMI. A significant increase in leptin levels only became evident after 6 months of treatment [2.99 μg/l (2.60) vs. 4.21 μg/l (3.84), P< 0.05]. Leptin levels also significantly increased after transsphenoidal surgery [3.05 μg/l (5.73) vs. 5.19 μg/l (4.93), P< 0.05]. The positive correlation between serum leptin concentrations and BMI was restored in acromegalic patients both after treatment with Sandostatin® LAR® (r= 0.62, P < 0.05) and after surgery (r = 0.81, P < 0.05). CONCLUSION. Leptin concentrations were decreased in patients with active acromegaly and lowering GH by either Sandostatin® LAR® or transsphenoidal surgery led to an increase in leptin concentrations.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_HK
dc.relation.ispartofClinical Endocrinologyen_HK
dc.rightsClinical Endocrinology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAcromegaly - Blood - Surgeryen_US
dc.subject.meshAdulten_US
dc.subject.meshAnalysis Of Varianceen_US
dc.subject.meshBody Mass Indexen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshDelayed-Action Preparationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGrowth Hormone - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshInsulin-Like Growth Factor I - Analysisen_US
dc.subject.meshLeptin - Blooden_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOctreotide - Administration & Dosageen_US
dc.subject.meshSomatostatin - Analogs & Derivativesen_US
dc.subject.meshTime Factorsen_US
dc.titleEffect of Sandostatin® LAR® on serum leptin levels in patients with acromegalyen_HK
dc.typeArticleen_HK
dc.identifier.emailTan, KCB: kcbtan@hku.hken_HK
dc.identifier.emailTso, AWK: awk.tso@gmail.comen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityTan, KCB=rp00402en_HK
dc.identifier.authorityTso, AWK=rp00535en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2265.2001.01180.xen_HK
dc.identifier.pmid11167923-
dc.identifier.scopuseid_2-s2.0-0035138001en_HK
dc.identifier.hkuros56586-
dc.identifier.hkuros66541-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035138001&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume54en_HK
dc.identifier.issue1en_HK
dc.identifier.spage31en_HK
dc.identifier.epage35en_HK
dc.identifier.isiWOS:000166984600006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTan, KCB=8082703100en_HK
dc.identifier.scopusauthoridTso, AWK=6701371436en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats